Eye Affecting Patents (Class 514/20.8)
  • Patent number: 10729747
    Abstract: The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: August 4, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: B. Chia Soo, Kang Ting, Zhong Zheng
  • Patent number: 10456396
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: October 29, 2019
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Patent number: 10420736
    Abstract: The present invention addresses the problem of providing an intraocular irrigating solution that allows the intraocular tissue to be sufficiently protected during ophthalmic surgery and further has high safety. The problem is solved by an intraocular irrigating solution containing at least one of active sulfur molecules of which examples include cysteine persulfide and glutathione persulfide.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 24, 2019
    Assignee: TOHOKU UNIVERSITY
    Inventors: Toru Nakazawa, Takaaki Akaike, Hiroshi Kunikata
  • Patent number: 10125165
    Abstract: The present disclosure relates to methods of preparing and crystallizing ?-turn cyclic peptidomimetic salts of formula I: where R1, R2, R3, R4, R5, R6, R7, R8, R10, X, Y and n are as defined in the specification. The present disclosure provides a more efficient route for preparing a crystalline form of ?-turn cyclic peptidomimetic compounds and salts thereof.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: November 13, 2018
    Assignee: MIMETOGEN PHARMACEUTICALS, INC.
    Inventors: Sébastien Rocchi, Chantal Devin, Wei Tian, Martin Bohlin
  • Patent number: 10010586
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthlamic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 3, 2018
    Assignee: Dompé farmaceutici S.p.A.
    Inventor: Alessandro Lambiase
  • Patent number: 9707267
    Abstract: The present invention relates to methods of treating dry eye using ?-turn peptidomimetic cyclic compounds or derivatives thereof. The ?-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 18, 2017
    Assignee: Mimetogen Pharmaceuticals, Inc.
    Inventors: Garth Cumberlidge, Karen Meerovitch, Teresa Lama, Horacio Uri Saragovi
  • Patent number: 9650607
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: May 16, 2017
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 9649340
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: May 16, 2017
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 9642865
    Abstract: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 9, 2017
    Assignee: The Johns Hopkins University
    Inventors: Jun Liu, Curtis Chong, David J. Sullivan
  • Patent number: 9593146
    Abstract: The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of pancreatic cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 14, 2017
    Assignee: AMCURE GMBH
    Inventors: Veronique Orian-Rousseau, Alexandra Matzke, Helmut Ponta
  • Patent number: 9586994
    Abstract: The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of breast cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 7, 2017
    Assignee: AMCURE GMBH
    Inventors: Veronique Orian-Rousseau, Alexandra Matzke, Helmut Ponta
  • Patent number: 9586993
    Abstract: Compounds, pharmaceutical compositions and methods for treating different forms of pancreatic cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 7, 2017
    Assignee: AMCURE GMBH
    Inventors: Veronique Orian-Rousseau, Alexandra Matzke, Helmut Ponta
  • Patent number: 9353162
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: May 31, 2016
    Assignees: NOVARTIS AG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Thirry Léveillard, Jose Alain Sahel, Saddek Mohand-Said, Olivier Poch, David Hicks, Carlos Alvarez
  • Patent number: 9327049
    Abstract: The present invention relates to an anti-adhesion polymer composition capable of supporting growth factor, which effectively exhibits anti-adhesion function and, at the same time, has an excellent adhesive property so as to be able to easily and continuously adhere to a wound site, has antibacterial and hemostatic properties, and is composed of an injectable formulation suitable for use in minimally invasive surgery, laparoscopic surgery or the like. The anti-adhesion polymer composition capable of supporting growth factor comprises: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6,000-20,000 Da; 0.03-5 wt % of gelatin; 0.03-5 wt % of chitosan; and distilled water.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: May 3, 2016
    Assignee: CG Bio Co., Ltd.
    Inventors: Jung Ju Kim, Jung Won So, Hyun Seung Ryu, Jun Hyuk Seo
  • Patent number: 9283237
    Abstract: Described herein are methods of inhibiting or reversing the progression of presbyopia in an eye by administering a ?L-crystallin electrostatic interaction inhibitor. Presbyopia is caused by aggregation of the soluble crystalline lens proteins called the crystallins, particularly ?L-crystallin. It has been found that the aggregation of ?L-crystallin is an electrostatic phenomenon and that electrostatic interaction inhibitors can be employed to prevent the formation of ?L-crystallin aggregates as well as to deaggregate already formed aggregates.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: March 15, 2016
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Murugappan Muthukumar, Zhaoyang Ou, Deniz Civay
  • Patent number: 9204996
    Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 8, 2015
    Assignee: Encore Health, LLC
    Inventors: Jonathan S. Till, Ronald D. Blum
  • Patent number: 9156882
    Abstract: The present invention relates to methods of treating dry eye using ?-turn peptidomimetic cyclic compounds or derivatives thereof. The ?-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 13, 2015
    Assignee: MIMETOGEN PHARMACEUTICALS, INC.
    Inventors: Garth Cumberlidge, Karen Meerovitch, Teresa Lama
  • Publication number: 20150147320
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: December 16, 2014
    Publication date: May 28, 2015
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Publication number: 20150140078
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150141340
    Abstract: The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and/or edema. The methods comprise administering to a subject an agent comprising a caveolin scaffolding domain. The present invention further encompasses methods of treating and/or preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventor: William C. Sessa
  • Publication number: 20150141348
    Abstract: The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 21, 2015
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
  • Publication number: 20150140077
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140075
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140080
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140079
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140081
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Patent number: 9034830
    Abstract: The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 19, 2015
    Assignee: INTRATUS, INC.
    Inventors: Padma Nanduri, T. Aaron Dyer
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150133388
    Abstract: A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide including at least one of acetylated ?A-crystallin, acetylated ?B-crystallin, acetylated fragments thereof having molecular chaperone activity, and/or polypeptide mimetics thereof that can inhibit pathological protein aggregation and/or pathological apoptosis.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventors: Ram Nagaraj, Rooban B. Nahomi
  • Patent number: 9029327
    Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 12, 2015
    Assignee: Affiris AG
    Inventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
  • Publication number: 20150126458
    Abstract: Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 7, 2015
    Inventors: Thomas Hohman, Janet Cheetham, Scott Whitcup, Erik Lippa
  • Publication number: 20150126457
    Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Inventors: Dennis J. Goebel, John Marshall
  • Patent number: 9023798
    Abstract: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 5, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Jess Thoene, Jeffrey Innis
  • Publication number: 20150119338
    Abstract: The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF? neutralizing activity, and inhibits TNF? activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.
    Type: Application
    Filed: February 7, 2013
    Publication date: April 30, 2015
    Inventors: Sung Wuk Kim, Seung Kook Park, Yeon Jung Song, Eun Sun Kim, Hyea Kyung Ahn, Jae Kap Jeong, Hung Keun Lee
  • Patent number: 9005651
    Abstract: A drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. A sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: April 14, 2015
    Assignee: Tohoku University
    Inventors: Toshiaki Abe, Nobuhiro Nagai, Hirokazu Kaji, Takeaki Kawashima, Matsuhiko Nishizawa, Koji Nishida
  • Patent number: 8999325
    Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: April 7, 2015
    Assignee: Aerpio Therapeutics, Inc
    Inventors: Kevin Peters, Robert Shalwitz
  • Publication number: 20150094260
    Abstract: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.
    Type: Application
    Filed: August 14, 2014
    Publication date: April 2, 2015
    Inventors: Liora BRAIMAN-WIKSMAN, Yuval Sagiv, Ofra Levy-Hacham, Tamar Tennenbaum
  • Publication number: 20150079179
    Abstract: The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 19, 2015
    Inventor: Gary P. COOK
  • Publication number: 20150079094
    Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 19, 2015
    Inventors: Joyce Tombran-Tink, Colin J. Barnstable
  • Publication number: 20150071877
    Abstract: A method for preparing a bioactive composition containing conditioned cell culture medium is disclosed. The method comprises culturing cells of two or more eukaryotic cell line to form conditioned culture media, separating the cultured cells from the conditioned culture media, and combining conditioned culture media to form a bioactive composition. Novel bioactive compositions, formulations and their use in treating of a variety of diseases and health conditions are also disclosed.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Inventors: Greg Maguire, Peter Friedman
  • Patent number: 8975229
    Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: March 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 8969306
    Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8962567
    Abstract: Disclosed is a treatment for ophthalmic diseases, more specifically, a pharmaceutical composition for treating ophthalmic diseases including a fusion protein of FK506 binding protein capable of penetrating into the ocular tissue as an active ingredient.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: February 24, 2015
    Assignee: Industry Academic Cooperation Foundation, Hallym University
    Inventors: Soo Young Choi, Dae Won Kim, Sung Ho Lee, Jinseu Park, Won Sik Eum
  • Patent number: 8957043
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: February 17, 2015
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20150045296
    Abstract: Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Applicant: XAVIER UNIVERSITY OF LOUISIANA
    Inventor: Partha S. Bhattacharjee
  • Publication number: 20150045302
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Angelo Corti, Flavio Curnis
  • Publication number: 20150044181
    Abstract: The invention provides compositions and kits including at least one nucleic acid or polypeptide molecule encoding for a mutant ChR2 protein. Methods of the invention include administering a composition comprising a mutant ChR2 to a subject to preserve, improve, or restore phototransduction. Preferably, the compositions and methods of the invention are provided to a subject having impaired vision, thereby restoring vision to normal levels.
    Type: Application
    Filed: March 5, 2013
    Publication date: February 12, 2015
    Inventor: Zhuo-hua Pan
  • Publication number: 20150038432
    Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 5, 2015
    Applicant: UNIVERSITE DE STRASBOURG
    Inventors: Vincent Marion, Anaïs Mockel, Hélène Dollfus
  • Publication number: 20150037350
    Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 5, 2015
    Applicant: UCL BUSINESS PLC
    Inventors: Anna L. Furmanski, Jose Ignacio Saldana, Tessa Crompton
  • Patent number: RE46922
    Abstract: An organic light-emitting display is disclosed. In one embodiment, the display includes i) a substrate, ii) a thin film transistor formed on the substrate, and comprising i) a gate electrode, ii) an active layer electrically insulated from the gate electrode, and iii) source and drain electrodes that are electrically connected to the active layer and iii) a first electrode electrically connected to the thin film transistor. The display further includes an intermediate layer formed on the first electrode and comprising an organic emission layer and a second electrode formed on the intermediate layer, wherein the source electrode or the drain electrode has an optical blocking portion extending in the direction of substrate thickness.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: June 26, 2018
    Assignee: Samsung Display Co., Ltd.
    Inventors: Jong-Han Jeong, Steve Y.G. Mo, Eun-Hyun Kim, Hyun-Sun Park